Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The possible differential effect of withdrawal of GH replacement on body composition compartments and regional bone mass is not known.

The researchers performed a randomized, single blind, placebo-controlled 36-month cross-over study of GH vs. placebo (PL) in adults with GHD and now report the effect of withdrawal of GH on percent body fat, lean mass, and bone density, as measured by dual energy x-ray absorptiometry.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, men only.

How the Study Was Run

In design terms this was a randomized, single-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

In this single-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

What Was Measured

The researchers performed a randomized, single blind, placebo-controlled 36-month cross-over study of GH vs. placebo (PL) in adults with GHD and now report the effect of withdrawal of GH on percent body fat, lean mass, and bone density, as measured by dual energy x-ray absorptiometry.

The subject headings attached to it are Absorptiometry, Photon, Age of Onset, Body Composition, Bone Density, Growth Hormone, Human Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.